Datasheet: Live Single Cell Functional Analysis with Beacon Discoveryâ„¢
Access Resource

Blog

Recent Advancements in Therapeutic Antibody Discovery: Bispecific Antibodies, ADCs, Fully Human Antibodies, and Technology Driving Antibody Discovery Forward

Antibody Discovery /

Therapeutic antibodies are transforming medicine, offering precision treatments for cancer, autoimmune diseases, and infections. Recent advancements in antibody discovery and engineering have accelerated the pace of therapeutic development, focusing on approaches such as bispecific antibodies, antibody-drug conjugates (ADCs), and fully humanized antibodies. This blog dives into recent trends and how platforms like the Beacon optofluidic […]

Recent Advancements in Therapeutic Antibody Discovery: Bispecific Antibodies, ADCs, Fully Human Antibodies, and Technology Driving Antibody Discovery Forward Read More »

Revolutionizing Bispecific Antibody Production Using the Beacon® Platform

Cell Line Development /

Bispecific Antibodies: An Emerging Therapeutic Paradigm Bispecific antibodies (bsAbs) are rapidly gaining momentum in the pharmaceutical industry as a revolutionary class of therapeutics. While monoclonal antibodies (mAbs) have dominated the biologics landscape for decades, bsAbs offer unique therapeutic mechanisms by targeting two different antigens simultaneously. This capability enables novel treatment strategies, particularly in cancer immunotherapy,

Revolutionizing Bispecific Antibody Production Using the Beacon® Platform Read More »

Unlocking Insights in Antibody Discovery: An Integrated Approach with the Beacon® Platform and PipeBio

Antibody Discovery /

Navigating the field of antibody discovery requires a careful balance of innovative methodologies and advanced technologies. Traditional approaches often face limitations due to biases, or risk overlooking critical insights. To overcome these challenges, a recent study delved into harnessing the combined power of Bruker’s Beacon® system and PipeBio software for antigen-specific and cross-reactive antibody discovery.

Unlocking Insights in Antibody Discovery: An Integrated Approach with the Beacon® Platform and PipeBio Read More »

Application Note: Revolutionizing Adoptive Cell Therapy Development with Bruker’s Beacon® Platform

T Cell Profiling, Cell Therapy, CAR T Therapy /

Adoptive cell therapy (ACT), the autologous or allogenic transplant of immune cells, is providing new hope in the ongoing battle against cancer. However, the path to harnessing the full potential of these therapies remains challenging, from understanding the intricate dynamics of individual cells to optimizing their therapeutic efficacy. Bruker’s Beacon® Platform emerges as a transformative

Application Note: Revolutionizing Adoptive Cell Therapy Development with Bruker’s Beacon® Platform Read More »

Exploring Species Diversity in Antibody Discovery on the Beacon® Optofluidic Platform

Antibody Discovery /

In the continually advancing field of biologics, it’s essential to search for new antibodies with distinct properties. The ability to screen primary B cells across diverse animal species broadens the diversity of recovered antibody sequences and increases the odds of finding the best antibody for any application across reagents, therapeutics, and basic health research. However,

Exploring Species Diversity in Antibody Discovery on the Beacon® Optofluidic Platform Read More »

Exploring a New Avenue in Vaccine Development: Targeting Conserved Epitopes with Broadly Neutralizing Antibodies

Antibody Discovery /

SARS-CoV-2’s ability to evolve quickly creates ongoing challenges for vaccine development. The spike protein, critical for the virus’s cell infection, undergoes rapid mutations, making antibodies less effective against new strains. Traditional vaccines, with their lengthy development and testing timelines, struggle to predict these evolutionary changes accurately, leading to a constant struggle to keep pace with

Exploring a New Avenue in Vaccine Development: Targeting Conserved Epitopes with Broadly Neutralizing Antibodies Read More »

Published in Scientific Reports: Understanding Antibody-Secreting Cells: A Closer Look at Cellular Dynamics with Optofluidic Precision

Antibody Discovery, Vaccines, Infectious Disease /

The behavior of early-minted antibody-secreting cells (ASC) or plasmablasts post-infection or vaccination plays a pivotal role in the immune response. Traditionally, long-lived plasma cells (LLPC) from the bone marrow are regarded as non-dividing, while blood ASCs are thought to be proliferative. Traditional technologies that average bulk data or measure surface phenotype alone miss critical functional

Published in Scientific Reports: Understanding Antibody-Secreting Cells: A Closer Look at Cellular Dynamics with Optofluidic Precision Read More »

Published in Frontiers in Molecular Medicine: Revolutionizing CAR-T Cell Manufacturing for Enhanced Therapeutic Responses with Bruker’s Single-Cell Instruments

CAR T Therapy /

In the rapidly evolving landscape of cancer treatment, chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapeutic approach, garnering FDA approval in 2017. However, the journey from initial success to widespread efficacy has been marked by challenges, prompting researchers to continuously reevaluate and refine CAR-T manufacturing processes. A recent review published

Published in Frontiers in Molecular Medicine: Revolutionizing CAR-T Cell Manufacturing for Enhanced Therapeutic Responses with Bruker’s Single-Cell Instruments Read More »